63959-47-7

Basic information

• Product Name: 2,4(1H,3H)-Pyrimidinedione, 6-amino-1,5-dimethyl-
• CAS NO: 63959-47-7
• Molecular Formula: C6H9N3O2
• Molecular Weight: 155.15500
• Mol File: 63959-47-7.mol
• Article Data: 2

Chemical Properties

• Melting Point: 327 °C (decomp)(Solv: water (7732-18-5))
• Density: 1.257±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2,4(1H,3H)-Pyrimidinedione, 6-amino-1,5-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4(1H,3H)-Pyrimidinedione, 6-amino-1,5-dimethyl-(63959-47-7)
• EPA Substance Registry System: 2,4(1H,3H)-Pyrimidinedione, 6-amino-1,5-dimethyl-(63959-47-7)

Safety Data

• Hazardous Substances Data: 63959-47-7(Hazardous Substances Data)

Usage

General Description

2,4(1H,3H)-Pyrimidinedione, 6-amino-1,5-dimethyl- is a chemical compound with a molecular formula C6H8N4O2. It is a derivative of pyrimidine and contains an amino group and two methyl groups. 2,4(1H,3H)-Pyrimidinedione, 6-amino-1,5-dimethyl- has been used in various pharmaceutical research and drug development studies. It exhibits potential biological activities such as antiviral, anticancer, and antimicrobial properties. Studies have shown that derivatives of this compound can inhibit the growth of cancer cells and display antiviral activity against certain viruses. Additionally, it has also been investigated for its potential use as a precursor in the synthesis of other pharmacologically active compounds.

Upstream product

• 632-07-5 2-cyanopropanoic acid 
• 623-59-6 N-acetyl-N'-methylurea 
• 1572-99-2 ethyl 2-cyanopropionate 
• 598-50-5 N-Methylurea 

Downstream Products

• 1609259-61-1 6-bromo-1,5-dimethylpyrimidine-2,4(1H,3H)-dione 
• 1643489-24-0 1,5-dimethyl-6-(2-methyl-4-((3-(trifluoromethyl)pyridin-2-yl)-oxy)phenyl)pyrimidine-2,4(1H,3H)-dione 

Relevant articles and documents

Synthesis and Pharmacological Evaluation of Noncatechol G Protein Biased and Unbiased Dopamine D1 Receptor Agonists

Noncatechol heterocycles have recently been discovered as potent and selective G protein biased dopamine 1 receptor (D1R) agonists with superior pharmacokinetic properties. To determine the structure-activity relationships centered on G protein or β-arrestin signaling bias, systematic medicinal chemistry was employed around three aromatic pharmacophores of the lead compound 5 (PF2334), generating a series of new molecules that were evaluated at both D1R Gs-dependent cAMP signaling and β-arrestin recruitment in HEK293 cells. Here, we report the chemical synthesis, pharmacological evaluation, and molecular docking studies leading to the identification of two novel noncatechol D1R agonists that are a subnanomolar potent unbiased ligand 19 (PW0441) and a nanomolar potent complete G protein biased ligand 24 (PW0464), respectively. These novel D1R agonists provide important tools to study D1R activation and signaling bias in both health and disease.